Open an account

PolyPid

PYPD · NASDAQ

$5.15+$0.27 (+5.53%)TodayMarket closed ·
Prev close $4.88

PYPD analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 6 analysts

Average $11.98 (+132.7% upside)

Low
$8.08
Now
$5.15
High
$14.70

Upgrades and downgrades

The latest rating actions, newest first

PYPD analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Jul 21, 2026MaintainsBuy
HC Wainwright & Co.Feb 11, 2026MaintainsBuy
Roth CapitalNov 13, 2025MaintainsBuy

The case for and against

Updated Jul 30, 2026

Bull case

PolyPid is well-positioned for success with a proven drug delivery technology, a strong pipeline of products, and a strategic partnership with Azurity Pharmaceuticals to support commercialization efforts. The company has also secured a significant amount of upfront and near-term payments, as well as potential milestone payments, which reduces financing risk and provides runway into profitability in 2029. With a strong management team and major advancements on the regulatory and commercial fronts, PolyPid has the potential to drive significant value for its shareholders in the long term.

Bear case

PolyPid is overvalued as a single asset company with a current market value of $177 million, given that their sole product candidate D-PLEX100 is still in clinical stages and faces competition in the anti-infective market. Although the company may receive significant upfront and milestone payments, their tiered royalty structure may not generate significant revenue in the near term and the success of their broader pipeline approach remains uncertain. Additionally, the company's financial stability may be at risk if they are unable to secure a commercial partnership for D-PLEX100.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.